Author Correction: Phenome-Wide Analysis of Copy Number Variants in 470,727 UK Biobank Genomes
Nature issued an author correction for the landmark study titled “Phenome‑wide analysis of copy number variants in 470,727 UK Biobank genomes.” The correction clarifies author contributions and institutional affiliations across a multinational AstraZeneca‑led consortium. The original research surveyed copy‑number variation (CNV) across nearly half a million participants, linking structural genomic changes to a broad spectrum of phenotypes. The article remains open‑access under a Creative Commons‑BY‑NC‑ND license, ensuring non‑commercial redistribution.
Imunon Inc (IMNN) Q4 2025 Earnings Call Transcript
Imunon reported Q3 2025 results, highlighting $5.3 million cash and a runway extending to mid‑Q1 2026 after a $4.5 million equity raise. Operating expenses fell 31% year‑over‑year, reducing monthly burn to $1.25‑$1.5 million. The pivotal OVATION 3 phase III ovarian‑cancer trial enrolled nine patients, surpassing internal targets,...
Tvardi Therapeutics Inc (TVRD) Q4 2025 Earnings Call Transcript
Teva reported Q4 2025 revenue of $4.5 billion, up 3% year‑over‑year, with adjusted EBITDA rising 6% and non‑GAAP EPS of $0.78, a 14% increase. The innovative portfolio contributed over $800 million, driven by AUSTEDO’s $618 million U.S. sales (+38%) and solid gains from...
A Longitudinal DNA Methylation Atlas and Its Link to Brain Structure and Mental Health
Researchers built a longitudinal DNA‑methylation atlas using the IMAGEN cohort of 506 adolescents, identifying 18 coordinated DNAm clusters that persist from age 14 to 19. The cluster architecture was validated in two older‑adult datasets (PPMI and ADNI), demonstrating lifespan stability....
Omeros Corp (OMER) Q4 2025 Earnings Call Transcript
Omeros Corp reported a Q3 2025 net loss of $30.9 million, but secured a transformative agreement with Novo Nordisk that could deliver up to $2.1 billion in upfront and milestone payments. The $240 million upfront cash will retire most short‑term debt and fund more...
Brainstorm Cell Therapeutics Inc (BCLI) Q4 2025 Earnings Call Transcript
Bristol‑Myers Squibb reported flat Q4 2025 revenue of $12.5 billion, with its growth portfolio expanding 15% YoY to $7.4 billion, offsetting roughly $4 billion of legacy decline. The company guided 2026 revenue between $46 billion and $47.5 billion, projecting 10‑15% growth for Eliquis despite a...
Milestone Scientific Inc (MLSS) Q4 2025 Earnings Call Transcript
Milestone Scientific reported that the FDA accepted the New Drug Application for lorundrostat and set a PDUFA target date of December 22, 2026. The company highlighted a surge in cash to $656.6 million, extending its financial runway to 2028, while net...
Galectin Therapeutics Inc (GALT) Q4 2025 Earnings Call Transcript
Altimmune reported a strengthened cash position of roughly $340 million, extending its runway through 2028 to fund a pivotal Phase III NASH trial. The company disclosed that the trial will enroll about 1,800 patients globally, testing 1.8 mg and 2.4 mg doses of its...
Mink Therapeutics Inc (INKT) Q4 2025 Earnings Call Transcript
MiNK Therapeutics reported a cash position of $14.3 million, extended through 2026 after a $1.2 million raise, while posting a $2.9 million net loss for Q4. Clinical data showed AGENT‑797 combined with PD‑1 achieved a median overall survival of roughly 23 months in heavily...
Cost of Cultured Meat: Workshop, Modeling, Resources, Feedback
The Unjournal is hosting an online workshop in late April/early May 2026 to refine cost projections for cultivated meat, especially cultured chicken, using an interactive Monte Carlo model. Participants—including bioprocess engineers, cell biologists, animal‑welfare funders, and industry practitioners—will shape belief‑elicitation surveys...
Light Switch for Life: Controlling Molecular Droplets with UV
Leiden’s Mashaghi Lab demonstrated that ultraviolet‑induced thymine‑dimer formation can serve as a molecular switch to rewire biomolecular condensates, allowing precise control of droplet stiffness, elasticity and fusion. The team paired this photochemical trigger with a novel microscope‑based platform that measures...
The BioPharm Brief: Talking Lifecycle Optimization, Strategic Investment, and Collaboration Shaping Growth Trajectory
The FDA has approved a higher-dose regimen of nusinersen (Spinraza) for spinal muscular atrophy, aiming to boost drug exposure and improve long‑term motor function. The approval underscores a broader industry shift toward lifecycle optimization of RNA‑targeted therapies. Simultaneously, biopharma firms...
NIH Opens the Bidding for $3B Professional Services Recompete
The National Institutes of Health has launched a new five‑year, $3 billion Professional Scientific and Technical Support Services (PSTSS) recompete to back intramural and vaccine research. The solicitation, due by 3 p.m. ET on April 27, seeks multiple awardees with expertise in microbiology,...
Copper-Loaded Starch Nanoparticles Can Target Bacteria in Microbial Communities
University of Michigan researchers have engineered copper‑loaded starch nanoparticles that release antibacterial copper ions when specific bacteria degrade the starch carrier. The positively charged particles preferentially bind to bacterial surfaces and demonstrated potent activity against Staphylococcus aureus and Bacillus subtilis...
Scaling Certainty
Precision medicine is shifting pharma from a volume‑driven model to one focused on early patient identification and diagnostic certainty. Real‑world studies show genomic profiling yields actionable insights in about 61% of advanced solid‑tumor cases, yet only a fraction of patients...
HealthcareWATCH
Within3 unveiled Dataverse, a unified real‑world data ecosystem that merges electronic health records, claims, and specialty analytics to sharpen pharmaceutical launch decisions. Avalere Health released a global framework to broaden genomic profiling in cancer care, while Emota’s report highlighted rising...
York Researchers Identify ESB2 Protein, Solving 40‑Year Sleeping Sickness Mystery
University of York scientists have identified the ESB2 protein that enables the African trypanosome to edit its own surface coat, resolving a four‑decade‑old mystery in sleeping‑sickness biology. The discovery reveals a precise genetic‑editing mechanism and points to novel drug targets.
NUS Unveils Clinical-Grade Wearable Sensor That Reads Fatigue and Stress in Real Time
Researchers at the National University of Singapore have launched a skin‑conforming hydrogel wearable that delivers clinical‑grade ECG and blood‑pressure data while users move, classifying fatigue with 92% accuracy. The breakthrough could give biohackers and employers a continuous, objective view of...
Inventiva Reports 2025 Full Year Results and Provides a Business Update
Inventiva posted 2025 revenues of €4.5 million (≈ $4.9 million) and ended the year with €99.3 million ($108 million) in cash and €131.6 million ($143 million) in short‑term deposits. The company raised $172.5 million (≈ €149 million) in a U.S. public offering and expects its cash runway to last until...
Mantis Biotech Launches AI‑driven Digital Twins to Create Synthetic Data for Drug Discovery
New York‑based Mantis Biotech unveiled an AI platform that builds physics‑based digital twins of humans, producing synthetic biomedical datasets for drug discovery and other high‑risk biomedical research. The startup says the technology can fill data gaps in rare diseases and...
RFK Jr.’s Peptide Deregulation Threatens the Foundations of Drug Safety
HHS Secretary Robert F. Kennedy Jr announced on a podcast that the federal government will lift restrictions on 14 injectable peptides, allowing compounding pharmacies to produce and sell them without the usual FDA review. The move bypasses the scientific advisory...
BullFrog AI Shares Jump 126% After Sealing AI‑driven Drug Discovery Deal with Top Pharma
BullFrog AI Holdings saw its Nasdaq‑listed shares climb 126.24% to $1.15 after announcing a commercial agreement with a leading global pharmaceutical company. The deal gives the pharma partner exclusive access to a novel target candidate for major depressive disorder and...
SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too
The phase III SCOUT‑HCM trial showed that mavacamten (Camzyos) significantly reduced left ventricular outflow tract (LVOT) gradients in adolescents with obstructive hypertrophic cardiomyopathy (HCM) compared with placebo. Forty‑four patients aged 12‑17 were randomized to weight‑based doses of 2 or 5 mg daily, achieving a...
Autism Risk Genes Largely Shared Across Global Populations
Scientists have long identified autism risk genes mainly in European‑ancestry cohorts, leaving gaps for other populations. The GALA Consortium sequenced over 15,000 Latin American individuals, including 4,700 with autism, and found 35 genome‑wide significant risk genes. These genes show substantial...
Link Between Ceramide Transport and Cell Senescence Could Inform Aging Biology Research
University at Buffalo researchers discovered that impairment of the ceramide transfer protein (CERT) blocks ER‑to‑Golgi ceramide transport, causing ceramide buildup in the endoplasmic reticulum and triggering ER stress that drives replicative senescence. Pharmacological inhibition of CERT reproduced the senescent phenotype...
Drug Trials Snapshots: INLURIYO
Eli Lilly’s oral selective estrogen receptor degrader INLURIYO (imlunestrant) received FDA approval on September 25 2025 for adults with advanced ER‑positive, HER2‑negative breast cancer harboring an ESR1 mutation after endocrine therapy failure. The decision rests on the EMBER‑3 trial, which enrolled 874...
Efforts to Treat Neurodegenerative Disease by Altering the Gut Microbiome
Research increasingly shows that gut microbiome composition influences brain health, with age‑related dysbiosis linked to Alzheimer’s and Parkinson’s disease. Animal studies demonstrate that probiotic strains such as Lactobacillus and Bifidobacterium can reduce neuroinflammation and improve cognitive markers, while fecal microbiota...
After Missing Kezar Buyout in 2024, Tang Returns as CEO of Aurinia With $50M Offer
Kevin Tang, newly installed CEO of Aurinia Pharmaceuticals, has revived his bid for Kezar Life Sciences with a $50 million offer of $6.95 per share, roughly matching Kezar’s $47 million market cap. The proposal follows Tang’s earlier, unsuccessful $1.10‑per‑share attempt made through...
#ACC26: Merck Touts Comparator Data for Oral Cholesterol Drug
Merck reported that its experimental oral PCSK9 inhibitor, enlici‑tide, outperformed a range of commonly prescribed cholesterol‑lowering medicines in a head‑to‑head comparator trial. The data bring the drug a step closer to becoming the first oral PCSK9 therapy on the market....
Centivax Closes $37 Million Financing
Centivax, a clinical‑stage biotech focused on universal vaccines, closed an oversubscribed $37 million financing round led by Structure Fund. The round also attracted Meiji Seika Pharma, Sigmas Group, Kendall Capital Partners, and Stripe co‑founder Patrick Collison. The capital will fund pre‑clinical...
#AAD26 Roundup: Takeda, Alumis, Priovant and Incyte Take the Stage
At the American Academy of Dermatology (AAD) meeting in Denver, Takeda, Alumis, Priovant and Incyte each unveiled late‑stage dermatology data, ranging from novel biologics to targeted small molecules. Sanofi and Biogen also presented, highlighting mixed results in eczema and lupus...
Pharmaceutical Executive Daily: Eli Lilly Presses U.K. Government to Raise NHS Drug Pricing
Eli Lilly is pressuring the U.K. government to raise NHS drug prices and eliminate the VPAG rebate scheme before it resumes new investment in Britain. The company is also exploring outcome‑based pricing for its anti‑obesity medicines. In parallel, Lilly struck a...
Peptides Shift From Biomarkers to Feeling Control, Raising Risks
I think peptides are popular because they give people a feeling of power and control. One feels helpless when they can't sleep, stop scrolling, eat well or exercise consistently. A few injections wrestles back a feeling of control. Evidence...
A ‘Doomsday Vault’ of Microbes Could Save Species—Including Us
The Microbiota Vault Initiative (MVI), launched in 2023 at the University of Zurich, aims to preserve global microbial diversity by storing fecal, fermented‑food, soil, water and air samples. Its pilot phase collected 1,200 stool and 190 fermented‑food specimens from seven...
What if Deleting the Oncogenic Protein Is the Wrong Move?
The article questions the prevailing belief that fully degrading oncogenic proteins outperforms merely inhibiting them. While inhibition has become a cornerstone of targeted cancer therapy, the piece argues that outright removal can trigger unforeseen biological responses. It highlights that protein...
Discovery of Noma-Linked Bacteria Opens Path to Early Diagnosis and Prevention
Researchers at Liverpool School of Tropical Medicine have discovered a previously undescribed Treponema species strongly associated with noma, a fatal disease affecting impoverished children. Using metagenomic sequencing and machine learning on saliva samples, they identified the bacterium early in disease...
Researchers Compare Brain Markers Affected by Brief versus Lengthy Exposure to Alcohol in Mice
Researchers at Washington University in St. Louis examined how single versus repeated alcohol exposures affect gene‑regulatory mechanisms in mouse brains. They found that brief exposure altered epigenetic markers in select regions, while prolonged exposure produced changes across all examined areas,...
Gene Therapy Reduces Geographic Atrophy Lesion Growth
Ocugen’s phase‑2 ArMaDa trial of the modifier gene therapy OCU410 showed a 31% reduction in geographic atrophy lesion growth and a 27% slower rate of ellipsoid zone loss at the medium dose, with 55% of treated eyes achieving at least...
LQDA's Superior Delivery Threatens UTHR's Orphan Edge
The $UTHR news today is great for IPF patients. But it is also very good news for $LQDA given they have better delivery of the same drug. UTHR has 7-year orphan protection in IPF, but that can be overcome by...
Depression Improves with Mebufotenin
A phase‑2b trial of inhaled mebufotenin (GH001) in 81 adults with treatment‑resistant depression showed rapid symptom relief, with 57.5% of the active‑treatment group achieving remission by day 8 versus none on placebo. The mean MADRS score fell by 15.2 points compared...
How a Growth Factor and SIRT1 Might Combat Disc Degeneration
Researchers reported that administering the metabolic hormone FGF21 boosts SIRT1 expression, which in turn activates the PINK1‑Parkin mitophagy pathway and reduces cellular senescence in intervertebral disc cells. In a rat model of puncture‑induced disc degeneration, FGF21 treatment partially restored nucleus...
PTAB Upholds Seer's Nano‑Particle Protein Enrichment Patent, Securing 23 Claims
The U.S. Patent Trial and Appeal Board affirmed 23 claims of Seer Inc.'s U.S. Patent No. 11,435,360 B2, preserving the core of its nano‑ and micro‑particle protein enrichment technology. The decision thwarts a challenge by Bruker subsidiaries PreOmics GmbH and...
Your Trial Recruitment Fails at the Website Front Door
Everyone complains that clinical trial recruitment is hard. Fair. 📍 But here is a question not enough people ask: Have you looked closely at your 𝘁𝗿𝗶𝗮𝗹 𝗿𝗲𝗰𝗿𝘂𝗶𝘁𝗺𝗲𝗻𝘁 𝘀𝗶𝘁𝗲? I ran one through https://t.co/f9IW600hsB. The science was solid. The 𝗺𝗲𝘀𝘀𝗮𝗴𝗶𝗻𝗴 𝘄𝗮𝘀 𝗻𝗼𝘁. 📉 That is the disconnect. Too...
Β‑NMN Restores SIRT1, Halting Liver Cell Aging
β-Nicotinamide mononucleotide prevents senescence and lipid accumulation in hepatic stellate cells by restoring SIRT1 function https://t.co/wyVHZ13QNK
Can One Laptop Control Multiple ONT Sequencers?
Anyone out there know if it is possible to simultaneously run multiple ONT sequencers from a single laptop?
Schwann Cell Exosomes Transfer Ribosomes, miRNAs for Nerve Repair
Glia-to-Axon Transfer of Ribosomes and miRNAs: A Novel Paradigm in Neural Repair "Schwann cell-derived exosomes thus represent both a novel mode of glia–neuron communication and a promising avenue for next-generation therapies for nerve regeneration." https://t.co/xU3zmkA5OA https://t.co/kK3FrVuN7T
Predicting Late‑Stage Trial Outcomes Could Speed Drug Development
Accurately predicting success and failure rate of late stage trials for new drugs could legitimately accelerate pharma. The late stages are where most of the time and money go, and are a bottleneck on bringing drugs to market today.
Prediction Claims 100% Success for MLTX in Psoriatic Arthritis
Really interesting. One of their predictions is 100% success chance for $MLTX in psoriatic arthritis.
Setidegrasib’s KRAS Degradation Still Unproven in Cancer
Elegant in theory, unproven in practice: setidegrasib and the case (or not) for KRAS degradation in NSCLC and pancreatic cancer: https://t.co/NuaOJ2amgn https://t.co/i9FpK4W19W
Lilly‑InsilicoMeds Partnership Grows to $2.75 B
30March: How did @EliLillyandCo and @InSilicoMeds begin and expand their collaboration into the up-to-$2.75B partnership announced Sunday? Read about $LLY and $3696 in the latest for @GENbio from me and colleague @xiaofei_lin: https://t.co/KtXOWFjGdq